Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 75

1.

French "real life" experience of clofarabine in children with refractory or relapsed acute lymphoblastic leukaemia.

Trioche P, Nelken B, Michel G, Pellier I, Petit A, Bertrand Y, Rohrlich P, Schmitt C, Sirvent N, Boutard P, Margueritte G, Pautard B, Ducassou S, Plantaz D, Robert A, Thomas C, Desseaux K, Chevret S, Baruchel A.

Exp Hematol Oncol. 2012 Dec 10;1(1):39. doi: 10.1186/2162-3619-1-39.

2.

Clofarabine, cyclophosphamide and etoposide as single-course re-induction therapy for children with refractory/multiple relapsed acute lymphoblastic leukaemia.

Locatelli F, Testi AM, Bernardo ME, Rizzari C, Bertaina A, Merli P, Pession A, Giraldi E, Parasole R, Barberi W, Zecca M.

Br J Haematol. 2009 Nov;147(3):371-8. doi: 10.1111/j.1365-2141.2009.07882.x. Epub 2009 Aug 29.

PMID:
19747360
3.

Refractory acute lymphoblastic leukemia in Chinese children: bridging to stem cell transplantation with clofarabine, cyclophosphamide and etoposide.

Liu AP, Lee V, Li CK, Ha SY, Chiang AK.

Ann Hematol. 2016 Feb;95(3):501-7. doi: 10.1007/s00277-015-2577-7. Epub 2015 Dec 15.

PMID:
26666536
4.

Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia.

Jeha S, Gaynon PS, Razzouk BI, Franklin J, Kadota R, Shen V, Luchtman-Jones L, Rytting M, Bomgaars LR, Rheingold S, Ritchey K, Albano E, Arceci RJ, Goldman S, Griffin T, Altman A, Gordon B, Steinherz L, Weitman S, Steinherz P.

J Clin Oncol. 2006 Apr 20;24(12):1917-23.

PMID:
16622268
5.

[Therapeutic effect of clofarabine in children with relapsed or refractory acute lymphoblastic leukemia].

Suo P, Zhang LP, Wu J, Lu AD, Wang B, Zuo YX, Cheng YF, Liu GL.

Zhongguo Dang Dai Er Ke Za Zhi. 2013 Jun;15(6):444-7. Chinese.

6.

Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.

Hagemeister FB.

Cancer Chemother Pharmacol. 2002 May;49 Suppl 1:S13-20. Epub 2002 Apr 12. Review.

PMID:
12042984
8.

Minimal residual disease status as a predictor of relapse after allogeneic bone marrow transplantation for children with acute lymphoblastic leukaemia.

Knechtli CJ, Goulden NJ, Hancock JP, Harris EL, Garland RJ, Jones CG, Grandage VL, Rowbottom AW, Green AF, Clarke E, Lankester AW, Potter MN, Cornish JM, Pamphilon DH, Steward CG, Oakhill A.

Br J Haematol. 1998 Aug;102(3):860-71.

PMID:
9722317
9.

Chimerism and minimal residual disease monitoring after reduced intensity conditioning (RIC) allogeneic transplantation.

Pérez-Simón JA, Caballero D, Diez-Campelo M, Lopez-Pérez R, Mateos G, Cañizo C, Vazquez L, Vidriales B, Mateos MV, Gonzalez M, San Miguel JF.

Leukemia. 2002 Aug;16(8):1423-31. Review.

10.

[Clinical study of allogeneic hematopoietic stem cell transplantation for relapsed/refractory acute lymphocytic leukemia].

Ma X, Wu DP, Sun AN, Fu ZZ, Tang XW, Wu XJ, Liu YJ, Qiu HY, Miao M, Han Y, Jin ZM, Zhao Y, Xue SL, Wang Y, Chen SN, He GS, Zhou HX, Chang HR.

Zhonghua Xue Ye Xue Za Zhi. 2009 Feb;30(2):73-6. Chinese.

PMID:
19563014
13.

Prospective monitoring of BCR-ABL1 transcript levels in patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia undergoing imatinib-combined chemotherapy.

Yanada M, Sugiura I, Takeuchi J, Akiyama H, Maruta A, Ueda Y, Usui N, Yagasaki F, Yujiri T, Takeuchi M, Nishii K, Kimura Y, Miyawaki S, Narimatsu H, Miyazaki Y, Ohtake S, Jinnai I, Matsuo K, Naoe T, Ohno R; Japan Adult Leukemia Study Group.

Br J Haematol. 2008 Nov;143(4):503-10. doi: 10.1111/j.1365-2141.2008.07377.x.

PMID:
18986386
14.

Intensive salvage chemotherapy for primary refractory or first relapsed adult acute lymphoblastic leukemia: results of a prospective trial.

Martino R, Bellido M, Brunet S, Altés A, Sureda A, Guárdia R, Aventín A, Nomdedéu JF, Domingo-Albós A, Sierra J.

Haematologica. 1999 Jun;84(6):505-10.

15.

High-dose ifosfamide in combination with etoposide and epirubicin (IVE) in the treatment of relapsed/refractory Hodgkin's disease and non-Hodgkin's lymphoma: a report on toxicity and efficacy.

Proctor SJ, Taylor PR, Angus B, Wood K, Lennard AL, Lucraft H, Carey PJ, Stark A, Iqbal A, Haynes A, Russel N, Leonard RC, Culligan D, Conn J, Jackson GH.

Eur J Haematol Suppl. 2001 Jul;64:28-32.

PMID:
11486397
16.

[Comparison of the efficiency of CHOP-based regimen with or without high dose consolidation treatment combined with hematopoietic stem cell transplantation in 63 lymphoblastic lymphoma patients].

Qin Y, Shi YK, He XH, Han XH, Zhou SY, Liu P, Yang JL, Yang S, Zhang CG, Dong M, Zhou LQ, Wang JW, Feng FY, Sun Y.

Zhonghua Zhong Liu Za Zhi. 2009 Jun;31(6):469-73. Chinese.

PMID:
19950562
17.
18.

Second allogeneic hematopoietic stem cell transplantation as treatment for leukemia relapsing following a first transplant.

Blau IW, Basara N, Bischoff M, Günzelmann S, Römer E, Kirsten D, Schmetzer B, Kiehl MG, Fauser AA.

Bone Marrow Transplant. 2000 Jan;25(1):41-5.

19.

Phase 1 study of clofarabine in pediatric patients with relapsed/refractory acute lymphoblastic leukemia in Japan.

Koh K, Ogawa C, Okamoto Y, Kudo K, Inagaki J, Morimoto T, Mizukami H, Ecstein-Fraisse E, Kikuta A.

Int J Hematol. 2016 Aug;104(2):245-55. doi: 10.1007/s12185-016-2004-4. Epub 2016 Apr 16.

PMID:
27086352
20.

Excellent outcome of allogeneic hematopoietic stem cell transplantation using a conditioning regimen with medium-dose VP-16, cyclophosphamide and total-body irradiation for adult patients with acute lymphoblastic leukemia.

Shigematsu A, Kondo T, Yamamoto S, Sugita J, Onozawa M, Kahata K, Endo T, Shiratori S, Ota S, Obara M, Wakasa K, Takahata M, Takeda Y, Tanaka J, Hashino S, Nishio M, Koike T, Asaka M, Imamura M.

Biol Blood Marrow Transplant. 2008 May;14(5):568-75. doi: 10.1016/j.bbmt.2008.02.018.

Supplemental Content

Support Center